252 related articles for article (PubMed ID: 26567749)
1. Exploring the Distribution of Prescription for Sulfonylureas in Patients with Type 2 Diabetes According to Cardiovascular Risk Factors Within a Canadian Primary Care Setting.
Farahani P; Khan S; Oatway M; Dziarmaga A
J Popul Ther Clin Pharmacol; 2015; 22(3):e228-36. PubMed ID: 26567749
[TBL] [Abstract][Full Text] [Related]
2. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
4. Sulfonylurea and the Heart: Theoretically a Compounded Question from a Pathophysiological Perspective.
Farahani P
J Popul Ther Clin Pharmacol; 2016 Sep; 23(3):e193-e195. PubMed ID: 27783474
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: Results of randomized controlled trials and observational studies.
Scheen AJ
Diabetes Metab; 2018 Nov; 44(5):386-392. PubMed ID: 30126735
[TBL] [Abstract][Full Text] [Related]
6. [Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey].
Vrablík M; Chmelík Z; Lánská V
Vnitr Lek; 2014 Nov; 60(11):991-7. PubMed ID: 25600047
[TBL] [Abstract][Full Text] [Related]
7. Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.
Ou SM; Shih CJ; Chao PW; Chu H; Kuo SC; Lee YJ; Wang SJ; Yang CY; Lin CC; Chen TJ; Tarng DC; Li SY; Chen YT
Ann Intern Med; 2015 Nov; 163(9):663-72. PubMed ID: 26457538
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
10. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women.
Li Y; Hu Y; Ley SH; Rajpathak S; Hu FB
Diabetes Care; 2014 Nov; 37(11):3106-13. PubMed ID: 25150157
[TBL] [Abstract][Full Text] [Related]
11. Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a large commercial database.
Beachler DC; Fernandes G; Deshpande G; Jemison J; Lyons JG; Lanes S; Liu J; McNeill A
Curr Med Res Opin; 2018 Jun; 34(6):1061-1069. PubMed ID: 29264933
[TBL] [Abstract][Full Text] [Related]
12. All-cause and cardiovascular mortality associated with sulphonylurea and metformin therapy in type 2 diabetes.
Ioacara S; Guja C; Reghina A; Martin S; Sirbu A; Fica S
Endocr Res; 2018 May; 43(2):97-105. PubMed ID: 29308936
[TBL] [Abstract][Full Text] [Related]
13. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study.
Douros A; Dell'Aniello S; Yu OHY; Filion KB; Azoulay L; Suissa S
BMJ; 2018 Jul; 362():k2693. PubMed ID: 30021781
[TBL] [Abstract][Full Text] [Related]
14. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study.
Gamble JM; Chibrikov E; Twells LK; Midodzi WK; Young SW; MacDonald D; Majumdar SR
Lancet Diabetes Endocrinol; 2017 Jan; 5(1):43-52. PubMed ID: 27865756
[TBL] [Abstract][Full Text] [Related]
15. Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic.
Kannan S; Pantalone KM; Matsuda S; Wells BJ; Karafa M; Zimmerman RS
J Diabetes; 2016 Mar; 8(2):279-85. PubMed ID: 25929426
[TBL] [Abstract][Full Text] [Related]
16. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
17. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
18. Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction.
Abdelmoneim AS; Welsh RC; Eurich DT; Simpson SH
Int J Cardiol; 2016 Jan; 202():126-30. PubMed ID: 26386939
[TBL] [Abstract][Full Text] [Related]
19. Mortality and Cardiovascular Risk of Sulfonylureas in South Asian, Chinese and Other Canadians with Diabetes.
Ke C; Morgan S; Smolina K; Gasevic D; Qian H; Khan N
Can J Diabetes; 2017 Apr; 41(2):150-155. PubMed ID: 27776891
[TBL] [Abstract][Full Text] [Related]
20. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?
Leibowitz G; Cerasi E
Diabetologia; 1996 May; 39(5):503-14. PubMed ID: 8739909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
